Rybelsus (oral semaglutide, diabetes label)
The diabetes tablet of semaglutide. Novo publishes no cash price — the $25 is a copay card, not a price.
- Medication
- brand
- Form
- pill
Novo publishes no self-pay price for Rybelsus. Its savings card offers 'as little as $25' for a 1-, 2- or 3-month prescription for eligible commercially insured patients, with Novo's own contribution capped at $100 a month — so the $25 is reached only where insurance already covers most of the cost.
How much does Rybelsus (oral semaglutide, diabetes label) cost a month?
halfrx records no verified price for Rybelsus (oral semaglutide, diabetes label): nothing it publishes states an all-in monthly figure, so this medication carries no price here rather than a guess. What it costs once titrated is not published, which is a fact about the seller rather than a gap in the data. The diabetes tablet of semaglutide. Novo publishes no cash price — the $25 is a copay card, not a price. No FTC action, state action, BBB F grade or FDA warning letter is recorded against it. It scores 3.4 out of 10 on a published formula that is arithmetic over these stored fields, not an editor's opinion. Novo publishes no self-pay price for Rybelsus. The medication is the branded, FDA-approved product rather than a compounded copy. The page rests on 1 cited source, at least one of them a manufacturer, regulator or journal. Molecule: semaglutide.
No clinician has reviewed this page. Every clinical statement on it is drawn from the FDA label or the trial cited beside it, and every price carries the date it was verified — but that is sourcing, not medical review, and the two are not the same thing. What we do and do not check · Who checked the price
Pros
Cons
- −Novo publishes no cash price, so the figure anyone without insurance actually pays is not discoverable in advance.[1]
- −The card caps Novo's contribution at $100 a month: with no coverage it does close to nothing, which is the opposite of how '$25' reads.[1]
- −Doses are lower than the Wegovy tablet's, so it is the diabetes product rather than the weight one — and using it for weight is off-label.[1]
- −Absorption depends on taking it fasting with a small sip of water and waiting 30 minutes, which is a stricter routine than a weekly injection.[1]
How this score is built
- 0.0/3.5Evidence — no pivotal trial for this product
- 3.0/3Approval — FDA approved for type 2 diabetes. Weight loss is off-label use.
- 0.0/2.5Cost — no verified price
- 0.4/1Caveats — −0.6 for off_label_for_weight, strict_dosing
Clinical evidence
FDA approved for type 2 diabetes. Weight loss is off-label use.
PIONEER trials in type 2 diabetes. Weight change was a secondary endpoint; the obesity trials of oral semaglutide were run at the higher doses sold as the Wegovy tablet rather than at these.
What Rybelsus costs without insurance, and every route to the same drug →
Sources
- [1] Save on RYBELSUS, Novo Nordiskprimary
Information only, not medical advice. Prices and terms change; the date above is when we last verified this one.